Compare iShares MSCI Canada (TSX) (EWC) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Canada (TSX) vs Summit Therapeutics Inc — how do they compare? iShares MSCI Canada (TSX) trades at $61.82, while Summit Therapeutics Inc trades at $15.1 (market cap $12.06B). The key difference: iShares MSCI Canada (TSX) is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| EWC | SMMT | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $61.51 | $26.98 |
52-Week Low | $47.00 | $12.55 |
Market Cap | — | $12.06B |
Enterprise Value | — | $11.39B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWC trades at $61.77, up 0.44% today, with a bullish technical signal from moving averages but overbought RSI levels. The ETF shows strong 2026 performance, though trailing the S&P 500, and faces trade tensions as U.S. tariffs on Canadian goods loom, potentially impacting exports excluding energy and potash.
Outlook is mixed: growth drivers include Canada's record exports and active ETF trends, but risks from tariff escalations and political uncertainty weigh. Investors balance double-digit returns against trade war volatility, with key support at $61.
Summit Therapeutics (SMMT) trades at $15.10, up 1.55% with a bullish technical signal and strong analyst support. The company shows negative profitability metrics with ROE at -192.5% and net income of -$1.08B for 2025, but maintains positive cash flow through financing activities. Recent developments include FDA review of ivonescimab with a November 2026 decision date and expansion into bladder cancer trials, driving investor optimism despite ongoing losses.
The investment case hinges on ivonescimab's regulatory approval potential, with a consensus price target of $27.90 representing 85% upside. Key risks include cash burn concerns, fiduciary duty investigations, and clinical trial outcomes. While fundamentals remain weak, the stock offers high-risk, high-reward potential for speculative biotech investors betting on successful drug commercialization.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares MSCI Canada (TSX)
EWC is a country-specific ETF that tracks the performance of the Canadian equity market. It provides exposure to large and mid-sized companies in Canada, with heavy concentrations in financials and energy, including Royal Bank of Canada, Shopify, and Enbridge.
Read more on EWC →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
